[논문]Loss of PGRMC1 Delays the Progression of Hepatocellular Carcinoma via Suppression of Pro-Inflammatory Immune Responses

Lee, Sang R.; Lee, Jong Geol; Heo, Jun H.; Jo, Seong Lae; Ryu, Jihoon; Kim, Globinna; Yon, Jung-Min; Lee, Myeong Sup; Lee, Geun-Shik; An, Beum-Soo; Shin, Hyun-Jin; Woo, Dong-Cheol; Baek, In-Jeoung; Hong, Eui-Ju

doi:10.3390/cancers13102438

[해외논문] Loss of PGRMC1 Delays the Progression of Hepatocellular Carcinoma via Suppression of Pro-Inflammatory Immune Responses 원문보기

Cancers, v.13 no.10, 2021년, pp.2438 -

Lee, Sang R. (College of Veterinary Medicine, Chungnam National University, Daejeon 34134, Korea) , Lee, Jong Geol (srlee5@naver.com (S.R.L.)) , Heo, Jun H. (heojh94@o.cnu.ac.kr (J.H.H.)) , Jo, Seong Lae (jsr7093@o.cnu.ac.kr (S.L.J.)) , Ryu, Jihoon (jihoon0511@cnu.ac.kr (J.R.)) , Kim, Globinna (shin0089@cnu.ac.kr (H.-J.S.)) , Yon, Jung-Min (Department of Convergence Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea) , Lee, Myeong Sup (superchecker@hanmail.net (J.G.L.)) , Lee, Geun-Shik (robichi1212@gmail.com (G.K.)) , An, Beum-Soo (yonjungmin@gmail.com (J.-M.Y.)) , Shin, Hyun-Jin (dcwoo@amc.seoul.kr (D.-C.W.)) , Woo, Dong-Cheol (College of Veterinary Medicine, Chungnam National University, Daejeon 34134, Korea) , Baek, In-Jeoung (srlee5@naver.com (S.R.L.)) , Hong, Eui-Ju (heojh94@o.cnu.ac.kr (J.H.H.))

Abstract ▼ AI-Helper

Simple SummaryProgesterone receptor membrane component 1 (PGRMC1) and epidermal growth factor receptor (EGFR) are highly expressed in various cancers. Here, we first analyzed two sets of clinical data and found that the levels of PGRMC1 and EGFR in hepatocellular carcinomas (HCCs) were both inversely correlated with the survival of HCC patients. Accordingly, by using a carcinogen-induced mouse model of HCC, we found that Pgrmc1 knockout suppressed HCC development and extended the lifespan of HCC-bearing mice. In the acute setting of high-dose carcinogen administration, Pgrmc1 knockout was associated with increases in hepatic necrosis and decreases in the production of the pro-inflammatory cytokine IL-6. Indeed, silencing of Pgrmc1 in murine macrophages suppressed IL-6 production and NF-κB activity, and this process was significantly mediated by EGFR. Our study shows that Pgrmc1 affects the development of HCCs by regulating the EGFR-mediated inflammatory responses. Pgrmc1 may serve as a biomarker and a therapeutic target of HCC.AbstractPgrmc1 is a non-canonical progesterone receptor related to the lethality of various types of cancer. PGRMC1 has been reported to exist in co-precipitated protein complexes with epidermal growth factor receptor (EGFR), which is considered a useful therapeutic target in hepatocellular carcinoma (HCC). Here, we investigated whether Pgrmc1 is involved in HCC progression. In clinical datasets, PGRMC1 transcription level was positively correlated with EGFR levels; importantly, PGRMC1 level was inversely correlated with the survival duration of HCC patients. In a diethylnitrosamine (DEN)-induced murine model of HCC, the global ablation of Pgrmc1 suppressed the development of HCC and prolonged the survival of HCC-bearing mice. We further found that increases in hepatocyte death and suppression of compensatory proliferation in the livers of DEN-injured Pgrmc1-null mice were concomitant with decreases in nuclear factor κB (NF-κB)-dependent production of interleukin-6 (IL-6). Indeed, silencing of Pgrmc1 in murine macrophages led to reductions in NF-κB activity and IL-6 production. We found that the anti-proinflammatory effect of Pgrmc1 loss was mediated by reductions in EGFR level and its effect was not observed after exposure of the EGFR inhibitor erlotinib. This study reveals a novel cooperative role of Pgrmc1 in supporting the EGFR-mediated development of hepatocellular carcinoma, implying that pharmacological suppression of Pgrmc1 may be a useful strategy in HCC treatment.

Keyword

참고문헌 (73)

1. Sung H. Ferlay J. Siegel R.L. Laversanne M. Soerjomataram I. Jemal A. Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J. Clin. 2021 71 209 249 10.3322/caac.21660 33538338

상세보기
2. Tu T. Buhler S. Bartenschlager R. Chronic viral hepatitis and its association with liver cancer Biol. Chem. 2017 398 817 837 10.1515/hsz-2017-0118 28455951

상세보기
3. Capece D. Fischietti M. Verzella D. Gaggiano A. Cicciarelli G. Tessitore A. Zazzeroni F. Alesse E. The inflammatory microenvironment in hepatocellular carcinoma: A pivotal role for tumor-associated macrophages Biomed. Res. Int. 2013 2013 187204 10.1155/2013/187204 23533994

상세보기
4. Forner A. Reig M. Bruix J. Hepatocellular carcinoma Lancet 2018 391 1301 1314 10.1016/S0140-6736(18)30010-2 29307467

상세보기
5. Kulik L. El-Serag H.B. Epidemiology and Management of Hepatocellular Carcinoma Gastroenterology 2019 156 477 491 10.1053/j.gastro.2018.08.065 30367835

상세보기
6. Hasskarl J. Sorafenib: Targeting multiple tyrosine kinases in cancer Recent Results Cancer Res. 2014 201 145 164 24756790

상세보기
7. Llovet J.M. Ricci S. Mazzaferro V. Hilgard P. Gane E. Blanc J.F. De Oliveira A.C. Santoro A. Raoul J.L. Forner A. Sorafenib in advanced hepatocellular carcinoma N. Engl. J. Med. 2008 359 378 390 10.1056/NEJMoa0708857 18650514

상세보기
8. Kudo M. Finn R.S. Qin S. Han K.-H. Ikeda K. Piscaglia F. Baron A. Park J.-W. Han G. Jassem J. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial Lancet 2018 391 1163 1173 10.1016/S0140-6736(18)30207-1 29433850

상세보기
9. Cheng A.-L. Kang Y.-K. Chen Z. Tsao C.-J. Qin S. Kim J.S. Luo R. Feng J. Ye S. Yang T.-S. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial Lancet Oncol. 2009 10 25 34 10.1016/S1470-2045(08)70285-7 19095497

상세보기
10. Ito Y. Takeda T. Sakon M. Tsujimoto M. Higashiyama S. Noda K. Miyoshi E. Monden M. Matsuura N. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma Br. J. Cancer 2001 84 1377 1383 10.1054/bjoc.2000.1580 11355950

상세보기
11. Buckley A.F. Burgart L.J. Sahai V. Kakar S. Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma Am. J. Clin. Pathol. 2008 129 245 251 10.1309/WF10QAAED3PP93BH 18208805

상세보기
12. Hopfner M. Sutter A.P. Huether A. Schuppan D. Zeitz M. Scherubl H. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma J. Hepatol. 2004 41 1008 1016 10.1016/j.jhep.2004.08.024 15582135

상세보기
13. Schiffer E. Housset C. Cacheux W. Wendum D. Rey C. Poupon R. Rosmorduc O. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis Hepatology 2005 41 307 314 10.1002/hep.20538 15660382

상세보기
14. Whittaker S. Marais R. Zhu A.X. The role of signaling pathways in the development and treatment of hepatocellular carcinoma Oncogene 2010 29 4989 5005 10.1038/onc.2010.236 20639898

상세보기
15. Philip P.A. Mahoney M.R. Allmer C. Thomas J. Pitot H.C. Kim G. Donehower R.C. Fitch T. Picus J. Erlichman C. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer J. Clin. Oncol. 2005 23 6657 6663 10.1200/JCO.2005.14.696 16170173

상세보기
16. Thomas M.B. Chadha R. Glover K. Wang X. Morris J. Brown T. Rashid A. Dancey J. Abbruzzese J.L. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma Cancer 2007 110 1059 1067 10.1002/cncr.22886 17623837

상세보기
17. Zhu A.X. Stuart K. Blaszkowsky L.S. Muzikansky A. Reitberg D.P. Clark J.W. Enzinger P.C. Bhargava P. Meyerhardt J.A. Horgan K. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma Cancer 2007 110 581 589 10.1002/cncr.22829 17583545

상세보기
18. Ezzoukhry Z. Louandre C. Trecherel E. Godin C. Chauffert B. Dupont S. Diouf M. Barbare J.-C. Maziere J.-C. Galmiche A. EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib Int. J. Cancer 2012 131 2961 2969 10.1002/ijc.27604 22514082

상세보기
19. Lin C.-H. Elkholy K.H. Wani N.A. Li D. Hu P. Barajas J.M. Yu L. Zhang X. Jacob S.T. Khan W.N. Ibrutinib Potentiates Antihepatocarcinogenic Efficacy of Sorafenib by Targeting EGFR in Tumor Cells and BTK in Immune Cells in the Stroma Mol. Cancer Ther. 2020 19 384 396 10.1158/1535-7163.MCT-19-0135 31582534

상세보기
20. Kabe Y. Nakane T. Koike I. Yamamoto T. Sugiura Y. Harada E. Sugase K. Shimamura T. Ohmura M. Muraoka K. Haem-dependent dimerization of PGRMC1/Sigma-2 receptor facilitates cancer proliferation and chemoresistance Nat. Commun. 2016 7 11030 10.1038/ncomms11030 26988023

상세보기
21. McCallum M.L. Pru C.A. Niikura Y. Yee S.-P. Lydon J.P. Peluso J.J. Pru J.K. Conditional Ablation of Progesterone Receptor Membrane Component 1 Results in Subfertility in the Female and Development of Endometrial Cysts Endocrinology 2016 157 3309 3319 10.1210/en.2016-1081 27309940

상세보기
22. Wu X.-J. Zhu Y. Downregulation of nuclear progestin receptor (Pgr) and subfertility in double knockouts of progestin receptor membrane component 1 (pgrmc1) and pgrmc2 in zebrafish Gen. Comp. Endocrinol. 2020 285 113275 10.1016/j.ygcen.2019.113275 31536721

상세보기
23. Wu X.-J. Thomas P. Zhu Y. Pgrmc1 Knockout Impairs Oocyte Maturation in Zebrafish Front. Endocrinol. 2018 9 560 10.3389/fendo.2018.00560 30319543

상세보기
24. Clark N.C. Pru C.A. Yee S.-P. Lydon J.P. Peluso J.J. Pru J.K. Conditional Ablation of Progesterone Receptor Membrane Component 2 Causes Female Premature Reproductive Senescence Endocrinology 2017 158 640 651 10.1210/en.2016-1701 28005395
25. Kim G. Lee J.G. Cheong S.-A. Yon J.-M. Lee M.S. Hong E.-J. Baek I.-J. Progesterone receptor membrane component 1 is required for mammary gland developmentdagger Biol. Reprod. 2020 103 1249 1259 10.1093/biolre/ioaa164 32915211

상세보기
26. Lee S.R. Yang H. Jo S.L. Lee Y.H. Lee H.W. Park B.-K. Hong E.-J. Suppressed estrogen supply via extra-ovarian progesterone receptor membrane component 1 in menopause J. Biomed. Res. 2021 2 1 10 10.7555/JBR.35.20200172 33911053

상세보기
27. Cahill M.A. Medlock A.E. Thoughts on interactions between PGRMC1 and diverse attested and potential hydrophobic ligands J. Steroid Biochem. Mol. Biol. 2017 171 11 33 10.1016/j.jsbmb.2016.12.020 28104494

상세보기
28. Thejer B.M. Adhikary P.P. Teakel S.L. Fang J. Weston P.A. Gurusinghe S. Anwer A.G. Gosnell M. Jazayeri J.A. Ludescher M. PGRMC1 effects on metabolism, genomic mutation and CpG methylation imply crucial roles in animal biology and disease BMC Mol. Cell Biol. 2020 21 26 10.1186/s12860-020-00268-z 32293262

상세보기
29. Thejer B.M. Adhikary P.P. Kaur A. Teakel S.L. Van Oosterum A. Seth I. Pajic M. Hannan K.M. Pavy M. Poh P. PGRMC1 phosphorylation affects cell shape, motility, glycolysis, mitochondrial form and function, and tumor growth BMC Mol. Cell Biol. 2020 21 24 10.1186/s12860-020-00256-3 32245408

상세보기
30. Lee S.R. Heo J.H. Jo S.L. Kim G. Kim S.J. Yoo H.J. Lee K.-P. Kwun H.-J. Shin H.-J. Baek I.-J. Progesterone receptor membrane component 1 reduces cardiac steatosis and lipotoxicity via activation of fatty acid oxidation and mitochondrial respiration Sci. Rep. 2021 11 8781 10.1038/s41598-021-88251-2 33888830

상세보기
31. Lee S.R. Choi W.-Y. Heo J.H. Huh J. Kim G. Lee K.-P. Kwun H.-J. Shin H.-J. Baek I.-J. Hong E.-J. Progesterone increases blood glucose via hepatic progesterone receptor membrane component 1 under limited or impaired action of insulin Sci. Rep. 2020 10 16316 10.1038/s41598-020-73330-7 33005004

상세보기
32. Cai G. Yang X. Ruan X. Wang J. Fang Y. Wei Y. Zhang Y. Gu M. Mueck A.O. Association of circulating Progesterone Receptor Membrane Component-1 (PGRMC1) with PGRMC1 expression in breast tumour tissue and with clinical breast tumour characteristics Maturitas 2020 140 64 71 10.1016/j.maturitas.2020.06.008 32972637

상세보기
33. Ruan X. Zhang Y. Mueck A.O. Willibald M. Seeger H. Fehm T. Brucker S. Neubauer H. Increased expression of progesterone receptor membrane component 1 is associated with aggressive phenotype and poor prognosis in ER-positive and negative breast cancer Menopause 2017 24 203 209 10.1097/GME.0000000000000739 27749742

상세보기
34. Lee S.R. Lee Y.H. Jo S.L. Heo J.H. Kim G. Lee G.-S. An B.-S. Baek I.-J. Hong E.-J. Absence of progesterone receptor membrane component 1 reduces migration and metastasis of breast cancer Cell Commun. Signal. 2021 19 42 10.1186/s12964-021-00719-w 33832499

상세보기
35. Zhao Y. Ruan X. Identification of PGRMC1 as a Candidate Oncogene for Head and Neck Cancers and Its Involvement in Metabolic Activities Front. Bioeng. Biotechnol. 2019 7 438 10.3389/fbioe.2019.00438 31970154

상세보기
36. Hampton K.K. Stewart R. Napier D. Claudio P.P. Craven R.J. PGRMC1 Elevation in Multiple Cancers and Essential Role in Stem Cell Survival Adv. Lung Cancer 2015 4 37 51 10.4236/alc.2015.43006

상세보기
37. Ahmed I.S. Rohe H.J. Twist K.E. Craven R.J. Pgrmc1 (progesterone receptor membrane component 1) associates with epidermal growth factor receptor and regulates erlotinib sensitivity J. Biol. Chem. 2010 285 24775 24782 10.1074/jbc.M110.134585 20538600

상세보기
38. Pedroza D.A. Rajamanickam V. Subramani R. Bencomo A. Galvez A. Lakshmanaswamy R. Progesterone receptor membrane component 1 promotes the growth of breast cancers by altering the phosphoproteome and augmenting EGFR/PI3K/AKT signalling Br. J. Cancer 2020 123 1326 1335 10.1038/s41416-020-0992-6 32704174

상세보기
39. Zhou F. Shang W. Yu X. Tian J. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment Med. Res. Rev. 2018 38 741 767 10.1002/med.21455 28621802

상세보기
40. Naugler W.E. Sakurai T. Kim S. Maeda S. Kim K. Elsharkawy A.M. Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production Science 2007 317 121 124 10.1126/science.1140485 17615358

상세보기
41. Shang N. Bank T. Ding X. Breslin P. Li J. Shi B. Qiu W. Caspase-3 suppresses diethylnitrosamine-induced hepatocyte death, compensatory proliferation and hepatocarcinogenesis through inhibiting p38 activation Cell Death Dis. 2018 9 558 10.1038/s41419-018-0617-7 29752472

상세보기
42. Goyal L. Muzumdar M.D. Zhu A.X. Targeting the HGF/c-MET pathway in hepatocellular carcinoma Clin. Cancer Res. 2013 19 2310 2318 10.1158/1078-0432.CCR-12-2791 23388504

상세보기
43. Chen J. Li X. Cheng Q. Ning D. Ma J. Zhang Z. Chen X. Jiang L. Effects of cyclin D1 gene silencing on cell proliferation, cell cycle, and apoptosis of hepatocellular carcinoma cells J. Cell Biochem. 2018 119 2368 2380 10.1002/jcb.26400 28885717

상세보기
44. Qu A. Jiang C. Cai Y. Kim J.-H. Tanaka N. Ward J.M. Shah Y.M. Gonzalez F.J. Role of Myc in hepatocellular proliferation and hepatocarcinogenesis J. Hepatol. 2014 60 331 338 10.1016/j.jhep.2013.09.024 24096051

상세보기
45. He G. Karin M. NF-kappaB and STAT3―Key players in liver inflammation and cancer Cell Res. 2011 21 159 168 10.1038/cr.2010.183 21187858

상세보기
46. Sakurai T. He G. Matsuzawa A. Yu G.-Y. Maeda S. Hardiman G. Karin M. Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis Cancer Cell 2008 14 156 165 10.1016/j.ccr.2008.06.016 18691550

상세보기
47. Maeda S. Kamata H. Luo J.-L. Leffert H. Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis Cell 2005 121 977 990 10.1016/j.cell.2005.04.014 15989949

상세보기
48. Schwabe R.F. Brenner D.A. Mechanisms of Liver Injury. I. TNF-alpha-induced liver injury: Role of IKK, JNK, and ROS pathways Am. J. Physiol. Liver Physiol. 2006 290 G583 G589
49. Jing Y. Sun K. Liu W. Sheng D. Zhao S. Gao L. Wei L. Tumor necrosis factor-alpha promotes hepatocellular carcinogenesis through the activation of hepatic progenitor cells Cancer Lett. 2018 434 22 32 10.1016/j.canlet.2018.07.001 29981431

상세보기
50. Luedde T. Schwabe R.F. NF-kappaB in the liver--linking injury, fibrosis and hepatocellular carcinoma Nat. Rev. Gastroenterol. Hepatol. 2011 8 108 118 10.1038/nrgastro.2010.213 21293511

상세보기
51. Lian Q. Wang S. Zhang G. Wang D. Luo G. Tang J. Chen L. Gu J. HCCDB: A Database of Hepatocellular Carcinoma Expression Atlas Genom. Proteom. Bioinform. 2018 16 269 275 10.1016/j.gpb.2018.07.003 30266410

상세보기
52. Tessitore L. Apoptosis and cell proliferation are involved in the initiation of liver carcinogenesis by a subnecrogenic dose of diethylnitrosamine in refed rats J. Nutr. 2000 130 104 110 10.1093/jn/130.1.104 10613775

상세보기
53. Ying T.S. Sarma D.S. Farber E. Role of acute hepatic necrosis in the induction of early steps in liver carcinogenesis by diethylnitrosamine Cancer Res. 1981 41 2096 2102 6113050

상세보기
54. Hong E.-J. Levasseur M.-P. Dufour C.R. Perry M.-C. Giguere V. Loss of estrogen-related receptor alpha promotes hepatocarcinogenesis development via metabolic and inflammatory disturbances Proc. Natl. Acad. Sci. USA 2013 110 17975 17980 10.1073/pnas.1315319110 24127579

상세보기
55. Yu L.-X. Ling Y. Wang H.-Y. Role of nonresolving inflammation in hepatocellular carcinoma development and progression NPJ Precis. Oncol. 2018 2 6 10.1038/s41698-018-0048-z 29872724

상세보기
56. Mantovani A. Allavena P. Sica A. Balkwill F.R. Cancer-related inflammation Nature 2008 454 436 444 10.1038/nature07205 18650914

상세보기
57. Scaffidi P. Misteli T. Bianchi M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation Nature 2002 418 191 195 10.1038/nature00858 12110890

상세보기
58. Qin L.X. Inflammatory immune responses in tumor microenvironment and metastasis of hepatocellular carcinoma Cancer Microenviron. 2012 5 203 209 10.1007/s12307-012-0111-1 22678823

상세보기
59. Tian Z. Hou X. Liu W. Han Z. Wei L. Macrophages and hepatocellular carcinoma Cell Biosci. 2019 9 79 10.1186/s13578-019-0342-7 31572568

상세보기
60. Cassetta L. Pollard J.W. Targeting macrophages: Therapeutic approaches in cancer Nat. Rev. Drug Discov. 2018 17 887 904 10.1038/nrd.2018.169 30361552

상세보기
61. Ruffell B. Coussens L.M. Coussens, Macrophages and therapeutic resistance in cancer Cancer Cell 2015 27 462 472 10.1016/j.ccell.2015.02.015 25858805

상세보기
62. Galdiero M.R. Bonavita E. Barajon I. Garlanda C. Mantovani A. Jaillon S. Tumor associated macrophages and neutrophils in cancer Immunobiology 2013 218 1402 1410 10.1016/j.imbio.2013.06.003 23891329

상세보기
63. Noy R. Pollard J.W. Tumor-associated macrophages: From mechanisms to therapy Immunity 2014 41 49 61 10.1016/j.immuni.2014.06.010 25035953

상세보기
64. Jiang J. Wang G.-Z. Wang Y. Huang H.-Z. Li W.-T. Qu X.-D. Hypoxia-induced HMGB1 expression of HCC promotes tumor invasiveness and metastasis via regulating macrophage-derived IL-6 Exp. Cell Res. 2018 367 81 88 10.1016/j.yexcr.2018.03.025 29571949

상세보기
65. Karin M. Greten F.R. NF-kappaB: Linking inflammation and immunity to cancer development and progression Nat. Rev. Immunol. 2005 5 749 759 10.1038/nri1703 16175180

상세보기
66. Lin Y. Higashisaka K. Shintani T. Maki A. Hanamuro S. Haga Y. Maeda S. Tsujino H. Nagano K. Fujio Y. Progesterone receptor membrane component 1 leads to erlotinib resistance, initiating crosstalk of Wnt/beta-catenin and NF-kappaB pathways, in lung adenocarcinoma cells Sci. Rep. 2020 10 4748 10.1038/s41598-020-61727-3 32179851

상세보기
67. Cahill M.A. Jazayeri J.A. Kovacevic Z. Richardson D.R. PGRMC1 regulation by phosphorylation: Potential new insights in controlling biological activity Oncotarget 2016 7 50822 50827 10.18632/oncotarget.10691 27448967

상세보기
68. Natarajan A. Wagner B. Sibilia M. The EGF receptor is required for efficient liver regeneration Proc. Natl. Acad. Sci. USA 2007 104 17081 17086 10.1073/pnas.0704126104 17940036

상세보기
69. Xia H. Dai X. Yu H. Zhou S. Fan Z. Wei G. Tang Q. Gong Q. Bi F. EGFR-PI3K-PDK1 pathway regulates YAP signaling in hepatocellular carcinoma: The mechanism and its implications in targeted therapy Cell Death Dis. 2018 9 269 10.1038/s41419-018-0302-x 29449645

상세보기
70. Fuchs B.C. Hoshida Y. Fujii T. Wei L. Yamada S. Lauwers G.Y. McGinn C.M. Deperalta D.K. Chen X. Kuroda T. Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma Hepatology 2014 59 1577 1590 10.1002/hep.26898 24677197

상세보기
71. Lanaya H. Natarajan A. Komposch K. Li L. Amberg N. Chen L. Wculek S.K. Hammer M. Zenz R. Peck-Radosavljevic M. EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation Nat. Cell Biol. 2014 16 972 977 10.1038/ncb3031 25173978

상세보기
72. Tsai H.-W. Ho C.-L. Cheng S.-W. Lin Y.-J. Chen C.-C. Cheng P.-N. Yen C.-J. Chang T.-T. Chiang P.-M. Chan S.-H. Progesterone receptor membrane component 1 as a potential prognostic biomarker for hepatocellular carcinoma World J. Gastroenterol. 2018 24 1152 1166 10.3748/wjg.v24.i10.1152 29563759

상세보기
73. Lee S.R. Kwon S.W. Kaya P. Lee Y.H. Lee J.G. Kim G. Lee G.-S. Baek I.-J. Hong E.-J. Loss of progesterone receptor membrane component 1 promotes hepatic steatosis via the induced de novo lipogenesis Sci. Rep. 2018 8 15711 10.1038/s41598-018-34148-6 30356113

상세보기

LOADING...

활용도 분석정보

상세보기

다운로드

내보내기

활용도 Top5 논문

해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.

표제어: PCR

동의어: Packet Collision Rate

용어 설명 출처 목록 (6)

용어 설명: PCR은 세균 특이성이 있는 primer를 이용하여 적은 수의 세균이 있을지라도 쉽게 검출할 수 있는 유용한 방법이며, 이를 이용하여 구강 내 치면세균막이나 타액에서 직접 세균을 검출할 수 있게 되었다[8].

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증